Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan
Identifieur interne : 000324 ( Istex/Corpus ); précédent : 000323; suivant : 000325Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan
Auteurs : Christopher G. Goetz ; Stanley Fahn ; Pablo Martinez-Martin ; Werner Poewe ; Cristina Sampaio ; Glenn T. Stebbins ; Matthew B. Stern ; Barbara C. Tilley ; Richard Dodel ; Bruno Dubois ; Robert Holloway ; Joseph Jankovic ; Jaime Kulisevsky ; Anthony E. Lang ; Andrew Lees ; Sue Leurgans ; Peter A. Lewitt ; David Nyenhuis ; C. Warren Olanow ; Olivier Rascol ; Anette Schrag ; Jeanne A. Teresi ; Jacobus J. Van Hilten ; Nancy LapelleSource :
- Movement Disorders [ 0885-3185 ] ; 2007-01.
English descriptors
Abstract
This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)–sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS‐UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve problematic areas. An MDS‐UPDRS committee prepared the revision using the recommendations of the published critique of the scale. Subcommittees developed new material that was reviewed by the entire committee. A 1‐day face‐to‐face committee meeting was organized to resolve areas of debate and to arrive at a working draft ready for clinimetric testing. The MDS‐UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Experiences of Daily Living; III, Motor Examination; and IV, Motor Complications. All items have five response options with uniform anchors of 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Several questions in Part I and all of Part II are written as a patient/caregiver questionnaire, so that the total rater time should remain approximately 30 minutes. Detailed instructions for testing and data acquisition accompany the MDS‐UPDRS in order to increase uniform usage. Multiple language editions are planned. A three‐part clinimetric program will provide testing of reliability, validity, and responsiveness to interventions. Although the MDS‐UPDRS will not be published until it has successfully passed clinimetric testing, explanation of the process, key changes, and clinimetric programs allow clinicians and researchers to understand and participate in the revision process. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21198
Links to Exploration step
ISTEX:F46244B722761F7710F83364D6F9965927CB98D5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan</title><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name><affiliation><mods:affiliation>Department of Neurology, Columbia University, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation><mods:affiliation>Department of Neuroepidemiology, Carlos III Institute, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Department of Pharmacology, Faculdade de Medicina de Lisboa, Lisboa, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Tilley, Barbara C" sort="Tilley, Barbara C" uniqKey="Tilley B" first="Barbara C." last="Tilley">Barbara C. Tilley</name><affiliation><mods:affiliation>Biostatistics, Bioinformatics Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA</mods:affiliation></affiliation></author><author><name sortKey="Dodel, Richard" sort="Dodel, Richard" uniqKey="Dodel R" first="Richard" last="Dodel">Richard Dodel</name><affiliation><mods:affiliation>Department of Neurology, Friedrich‐Wilhelms University, Bonn, Germany</mods:affiliation></affiliation></author><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation><mods:affiliation>Department of Neurology, Hôpital de la Salpetriere, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Holloway, Robert" sort="Holloway, Robert" uniqKey="Holloway R" first="Robert" last="Holloway">Robert Holloway</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><mods:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name><affiliation><mods:affiliation>Department of Neurology, Sant Pau Hospital, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation><mods:affiliation>Division of Applied and Interventional Research, University of Toronto, Toronto, Canada</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name><affiliation><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, University College, London, England</mods:affiliation></affiliation></author><author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name><affiliation><mods:affiliation>Department of Neurology, Wayne State University, Detroit, Michigan, USA</mods:affiliation></affiliation></author><author><name sortKey="Nyenhuis, David" sort="Nyenhuis, David" uniqKey="Nyenhuis D" first="David" last="Nyenhuis">David Nyenhuis</name><affiliation><mods:affiliation>Department of Neurology and Rehabilitation, University of Illinois, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse University, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation><mods:affiliation>Department of Clinical Neurosciences, University College, London, England</mods:affiliation></affiliation></author><author><name sortKey="Teresi, Jeanne A" sort="Teresi, Jeanne A" uniqKey="Teresi J" first="Jeanne A." last="Teresi">Jeanne A. Teresi</name><affiliation><mods:affiliation>Division of General Medicine, Columbia University, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Van Hilten, Jacobus J" sort="Van Hilten, Jacobus J" uniqKey="Van Hilten J" first="Jacobus J." last="Van Hilten">Jacobus J. Van Hilten</name><affiliation><mods:affiliation>Department of Neurology, Leiden University, Leiden, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Lapelle, Nancy" sort="Lapelle, Nancy" uniqKey="Lapelle N" first="Nancy" last="Lapelle">Nancy Lapelle</name><affiliation><mods:affiliation>Division of Preventive and Behavioral Medicine, University of Massachusetts, Worcester, Massachusetts, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F46244B722761F7710F83364D6F9965927CB98D5</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21198</idno><idno type="url">https://api.istex.fr/document/F46244B722761F7710F83364D6F9965927CB98D5/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000324</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan</title><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name><affiliation><mods:affiliation>Department of Neurology, Columbia University, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation><mods:affiliation>Department of Neuroepidemiology, Carlos III Institute, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Department of Pharmacology, Faculdade de Medicina de Lisboa, Lisboa, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Tilley, Barbara C" sort="Tilley, Barbara C" uniqKey="Tilley B" first="Barbara C." last="Tilley">Barbara C. Tilley</name><affiliation><mods:affiliation>Biostatistics, Bioinformatics Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA</mods:affiliation></affiliation></author><author><name sortKey="Dodel, Richard" sort="Dodel, Richard" uniqKey="Dodel R" first="Richard" last="Dodel">Richard Dodel</name><affiliation><mods:affiliation>Department of Neurology, Friedrich‐Wilhelms University, Bonn, Germany</mods:affiliation></affiliation></author><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation><mods:affiliation>Department of Neurology, Hôpital de la Salpetriere, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Holloway, Robert" sort="Holloway, Robert" uniqKey="Holloway R" first="Robert" last="Holloway">Robert Holloway</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><mods:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name><affiliation><mods:affiliation>Department of Neurology, Sant Pau Hospital, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation><mods:affiliation>Division of Applied and Interventional Research, University of Toronto, Toronto, Canada</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name><affiliation><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, University College, London, England</mods:affiliation></affiliation></author><author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name><affiliation><mods:affiliation>Department of Neurology, Wayne State University, Detroit, Michigan, USA</mods:affiliation></affiliation></author><author><name sortKey="Nyenhuis, David" sort="Nyenhuis, David" uniqKey="Nyenhuis D" first="David" last="Nyenhuis">David Nyenhuis</name><affiliation><mods:affiliation>Department of Neurology and Rehabilitation, University of Illinois, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse University, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation><mods:affiliation>Department of Clinical Neurosciences, University College, London, England</mods:affiliation></affiliation></author><author><name sortKey="Teresi, Jeanne A" sort="Teresi, Jeanne A" uniqKey="Teresi J" first="Jeanne A." last="Teresi">Jeanne A. Teresi</name><affiliation><mods:affiliation>Division of General Medicine, Columbia University, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Van Hilten, Jacobus J" sort="Van Hilten, Jacobus J" uniqKey="Van Hilten J" first="Jacobus J." last="Van Hilten">Jacobus J. Van Hilten</name><affiliation><mods:affiliation>Department of Neurology, Leiden University, Leiden, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Lapelle, Nancy" sort="Lapelle, Nancy" uniqKey="Lapelle N" first="Nancy" last="Lapelle">Nancy Lapelle</name><affiliation><mods:affiliation>Division of Preventive and Behavioral Medicine, University of Massachusetts, Worcester, Massachusetts, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-01">2007-01</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="41">41</biblScope><biblScope unit="page" to="47">47</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">F46244B722761F7710F83364D6F9965927CB98D5</idno><idno type="DOI">10.1002/mds.21198</idno><idno type="ArticleID">MDS21198</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>Unified Parkinson's Disease Rating Scale</term><term>clinimetrics</term><term>rating scales</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)–sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS‐UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve problematic areas. An MDS‐UPDRS committee prepared the revision using the recommendations of the published critique of the scale. Subcommittees developed new material that was reviewed by the entire committee. A 1‐day face‐to‐face committee meeting was organized to resolve areas of debate and to arrive at a working draft ready for clinimetric testing. The MDS‐UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Experiences of Daily Living; III, Motor Examination; and IV, Motor Complications. All items have five response options with uniform anchors of 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Several questions in Part I and all of Part II are written as a patient/caregiver questionnaire, so that the total rater time should remain approximately 30 minutes. Detailed instructions for testing and data acquisition accompany the MDS‐UPDRS in order to increase uniform usage. Multiple language editions are planned. A three‐part clinimetric program will provide testing of reliability, validity, and responsiveness to interventions. Although the MDS‐UPDRS will not be published until it has successfully passed clinimetric testing, explanation of the process, key changes, and clinimetric programs allow clinicians and researchers to understand and participate in the revision process. © 2006 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Christopher G. Goetz</name><affiliations><json:string>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Stanley Fahn</name><affiliations><json:string>Department of Neurology, Columbia University, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Pablo Martinez‐Martin</name><affiliations><json:string>Department of Neuroepidemiology, Carlos III Institute, Madrid, Spain</json:string></affiliations></json:item><json:item><name>Werner Poewe</name><affiliations><json:string>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Cristina Sampaio</name><affiliations><json:string>Department of Pharmacology, Faculdade de Medicina de Lisboa, Lisboa, Portugal</json:string></affiliations></json:item><json:item><name>Glenn T. Stebbins</name><affiliations><json:string>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Matthew B. Stern</name><affiliations><json:string>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item><json:item><name>Barbara C. Tilley</name><affiliations><json:string>Biostatistics, Bioinformatics Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA</json:string></affiliations></json:item><json:item><name>Richard Dodel</name><affiliations><json:string>Department of Neurology, Friedrich‐Wilhelms University, Bonn, Germany</json:string></affiliations></json:item><json:item><name>Bruno Dubois</name><affiliations><json:string>Department of Neurology, Hôpital de la Salpetriere, Paris, France</json:string></affiliations></json:item><json:item><name>Robert Holloway</name><affiliations><json:string>Department of Neurology, University of Rochester, Rochester, New York, USA</json:string></affiliations></json:item><json:item><name>Joseph Jankovic</name><affiliations><json:string>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</json:string></affiliations></json:item><json:item><name>Jaime Kulisevsky</name><affiliations><json:string>Department of Neurology, Sant Pau Hospital, Barcelona, Spain</json:string></affiliations></json:item><json:item><name>Anthony E. Lang</name><affiliations><json:string>Division of Applied and Interventional Research, University of Toronto, Toronto, Canada</json:string></affiliations></json:item><json:item><name>Andrew Lees</name><affiliations><json:string>Reta Lila Weston Institute of Neurological Studies, University College, London, England</json:string></affiliations></json:item><json:item><name>Sue Leurgans</name><affiliations><json:string>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Peter A. LeWitt</name><affiliations><json:string>Department of Neurology, Wayne State University, Detroit, Michigan, USA</json:string></affiliations></json:item><json:item><name>David Nyenhuis</name><affiliations><json:string>Department of Neurology and Rehabilitation, University of Illinois, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>C. Warren Olanow</name><affiliations><json:string>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Olivier Rascol</name><affiliations><json:string>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse University, Toulouse, France</json:string></affiliations></json:item><json:item><name>Anette Schrag</name><affiliations><json:string>Department of Clinical Neurosciences, University College, London, England</json:string></affiliations></json:item><json:item><name>Jeanne A. Teresi</name><affiliations><json:string>Division of General Medicine, Columbia University, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Jacobus J. Van Hilten</name><affiliations><json:string>Department of Neurology, Leiden University, Leiden, The Netherlands</json:string></affiliations></json:item><json:item><name>Nancy LaPelle</name><affiliations><json:string>Division of Preventive and Behavioral Medicine, University of Massachusetts, Worcester, Massachusetts, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>rating scales</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Unified Parkinson's Disease Rating Scale</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>clinimetrics</value></json:item></subject><language><json:string>eng</json:string></language><abstract>This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)–sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS‐UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve problematic areas. An MDS‐UPDRS committee prepared the revision using the recommendations of the published critique of the scale. Subcommittees developed new material that was reviewed by the entire committee. A 1‐day face‐to‐face committee meeting was organized to resolve areas of debate and to arrive at a working draft ready for clinimetric testing. The MDS‐UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Experiences of Daily Living; III, Motor Examination; and IV, Motor Complications. All items have five response options with uniform anchors of 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Several questions in Part I and all of Part II are written as a patient/caregiver questionnaire, so that the total rater time should remain approximately 30 minutes. Detailed instructions for testing and data acquisition accompany the MDS‐UPDRS in order to increase uniform usage. Multiple language editions are planned. A three‐part clinimetric program will provide testing of reliability, validity, and responsiveness to interventions. Although the MDS‐UPDRS will not be published until it has successfully passed clinimetric testing, explanation of the process, key changes, and clinimetric programs allow clinicians and researchers to understand and participate in the revision process. © 2006 Movement Disorder Society</abstract><qualityIndicators><score>7.748</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>2003</abstractCharCount><pdfWordCount>4748</pdfWordCount><pdfCharCount>30345</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>302</abstractWordCount></qualityIndicators><title>Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan</title><genre><json:string>Serial article</json:string></genre><host><volume>22</volume><pages><total>7</total><last>47</last><first>41</first></pages><issn><json:string>0885-3185</json:string></issn><issue>1</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21198</json:string></doi><id>F46244B722761F7710F83364D6F9965927CB98D5</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/F46244B722761F7710F83364D6F9965927CB98D5/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/F46244B722761F7710F83364D6F9965927CB98D5/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/F46244B722761F7710F83364D6F9965927CB98D5/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2007</date></publicationStmt><notesStmt><note>Boehringer‐Ingelheim USA</note><note>GlaxoSmithKline</note><note>Pfizer, Inc.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan</title><author><persName><forename type="first">Christopher G.</forename><surname>Goetz</surname></persName><note type="correspondence"><p>Correspondence: Department of Neurological Sciences, Rush University Medical Center, Suite 755, 1725 West Harrison Street, Chicago, IL 60612</p></note><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">Stanley</forename><surname>Fahn</surname></persName><affiliation>Department of Neurology, Columbia University, New York, New York, USA</affiliation></author><author><persName><forename type="first">Pablo</forename><surname>Martinez‐Martin</surname></persName><affiliation>Department of Neuroepidemiology, Carlos III Institute, Madrid, Spain</affiliation></author><author><persName><forename type="first">Werner</forename><surname>Poewe</surname></persName><affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</affiliation></author><author><persName><forename type="first">Cristina</forename><surname>Sampaio</surname></persName><affiliation>Department of Pharmacology, Faculdade de Medicina de Lisboa, Lisboa, Portugal</affiliation></author><author><persName><forename type="first">Glenn T.</forename><surname>Stebbins</surname></persName><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">Matthew B.</forename><surname>Stern</surname></persName><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation></author><author><persName><forename type="first">Barbara C.</forename><surname>Tilley</surname></persName><affiliation>Biostatistics, Bioinformatics Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA</affiliation></author><author><persName><forename type="first">Richard</forename><surname>Dodel</surname></persName><affiliation>Department of Neurology, Friedrich‐Wilhelms University, Bonn, Germany</affiliation></author><author><persName><forename type="first">Bruno</forename><surname>Dubois</surname></persName><affiliation>Department of Neurology, Hôpital de la Salpetriere, Paris, France</affiliation></author><author><persName><forename type="first">Robert</forename><surname>Holloway</surname></persName><affiliation>Department of Neurology, University of Rochester, Rochester, New York, USA</affiliation></author><author><persName><forename type="first">Joseph</forename><surname>Jankovic</surname></persName><affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</affiliation></author><author><persName><forename type="first">Jaime</forename><surname>Kulisevsky</surname></persName><affiliation>Department of Neurology, Sant Pau Hospital, Barcelona, Spain</affiliation></author><author><persName><forename type="first">Anthony E.</forename><surname>Lang</surname></persName><affiliation>Division of Applied and Interventional Research, University of Toronto, Toronto, Canada</affiliation></author><author><persName><forename type="first">Andrew</forename><surname>Lees</surname></persName><affiliation>Reta Lila Weston Institute of Neurological Studies, University College, London, England</affiliation></author><author><persName><forename type="first">Sue</forename><surname>Leurgans</surname></persName><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">Peter A.</forename><surname>LeWitt</surname></persName><affiliation>Department of Neurology, Wayne State University, Detroit, Michigan, USA</affiliation></author><author><persName><forename type="first">David</forename><surname>Nyenhuis</surname></persName><affiliation>Department of Neurology and Rehabilitation, University of Illinois, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">C. Warren</forename><surname>Olanow</surname></persName><affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</affiliation></author><author><persName><forename type="first">Olivier</forename><surname>Rascol</surname></persName><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse University, Toulouse, France</affiliation></author><author><persName><forename type="first">Anette</forename><surname>Schrag</surname></persName><affiliation>Department of Clinical Neurosciences, University College, London, England</affiliation></author><author><persName><forename type="first">Jeanne A.</forename><surname>Teresi</surname></persName><affiliation>Division of General Medicine, Columbia University, New York, New York, USA</affiliation></author><author><persName><forename type="first">Jacobus J.</forename><surname>Van Hilten</surname></persName><affiliation>Department of Neurology, Leiden University, Leiden, The Netherlands</affiliation></author><author><persName><forename type="first">Nancy</forename><surname>LaPelle</surname></persName><affiliation>Division of Preventive and Behavioral Medicine, University of Massachusetts, Worcester, Massachusetts, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-01"></date><biblScope unit="vol">22</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="41">41</biblScope><biblScope unit="page" to="47">47</biblScope></imprint></monogr><idno type="istex">F46244B722761F7710F83364D6F9965927CB98D5</idno><idno type="DOI">10.1002/mds.21198</idno><idno type="ArticleID">MDS21198</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)–sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS‐UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve problematic areas. An MDS‐UPDRS committee prepared the revision using the recommendations of the published critique of the scale. Subcommittees developed new material that was reviewed by the entire committee. A 1‐day face‐to‐face committee meeting was organized to resolve areas of debate and to arrive at a working draft ready for clinimetric testing. The MDS‐UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Experiences of Daily Living; III, Motor Examination; and IV, Motor Complications. All items have five response options with uniform anchors of 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Several questions in Part I and all of Part II are written as a patient/caregiver questionnaire, so that the total rater time should remain approximately 30 minutes. Detailed instructions for testing and data acquisition accompany the MDS‐UPDRS in order to increase uniform usage. Multiple language editions are planned. A three‐part clinimetric program will provide testing of reliability, validity, and responsiveness to interventions. Although the MDS‐UPDRS will not be published until it has successfully passed clinimetric testing, explanation of the process, key changes, and clinimetric programs allow clinicians and researchers to understand and participate in the revision process. © 2006 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>rating scales</term></item><item><term>Unified Parkinson's Disease Rating Scale</term></item><item><term>clinimetrics</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2005-05-17">Received</change><change when="2006-07-14">Registration</change><change when="2007-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/F46244B722761F7710F83364D6F9965927CB98D5/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="120"><doi origin="wiley" registered="yes">10.1002/mds.v22:1</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="2007-01">January 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="60" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21198</doi><idGroup><id type="unit" value="MDS21198"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2006 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2005-05-17"></event><event type="manuscriptRevised" date="2006-07-14"></event><event type="manuscriptAccepted" date="2006-07-14"></event><event type="firstOnline" date="2006-11-17"></event><event type="publishedOnlineFinalForm" date="2007-01-22"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2006-11-17"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">41</numbering><numbering type="pageLast">47</numbering></numberingGroup><correspondenceTo>Department of Neurological Sciences, Rush University Medical Center, Suite 755, 1725 West Harrison Street, Chicago, IL 60612</correspondenceTo><objectNameGroup><objectName elementName="appendix">APPENDIX</objectName></objectNameGroup><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21198.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="6"></count><count type="wordTotal" number="5235"></count></countGroup><titleGroup><title type="main" xml:lang="en">Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan</title><title type="short" xml:lang="en">MDS‐UPDRS</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Christopher G.</givenNames><familyName>Goetz</familyName></personName><contactDetails><email>cgoetz@rush.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Stanley</givenNames><familyName>Fahn</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Pablo</givenNames><familyName>Martinez‐Martin</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Cristina</givenNames><familyName>Sampaio</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Glenn T.</givenNames><familyName>Stebbins</familyName></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Matthew B.</givenNames><familyName>Stern</familyName></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Barbara C.</givenNames><familyName>Tilley</familyName></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Richard</givenNames><familyName>Dodel</familyName></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af9"><personName><givenNames>Bruno</givenNames><familyName>Dubois</familyName></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af10"><personName><givenNames>Robert</givenNames><familyName>Holloway</familyName></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af11"><personName><givenNames>Joseph</givenNames><familyName>Jankovic</familyName></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af12"><personName><givenNames>Jaime</givenNames><familyName>Kulisevsky</familyName></personName></creator><creator xml:id="au14" creatorRole="author" affiliationRef="#af13"><personName><givenNames>Anthony E.</givenNames><familyName>Lang</familyName></personName></creator><creator xml:id="au15" creatorRole="author" affiliationRef="#af14"><personName><givenNames>Andrew</givenNames><familyName>Lees</familyName></personName></creator><creator xml:id="au16" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Sue</givenNames><familyName>Leurgans</familyName></personName></creator><creator xml:id="au17" creatorRole="author" affiliationRef="#af15"><personName><givenNames>Peter A.</givenNames><familyName>LeWitt</familyName></personName></creator><creator xml:id="au18" creatorRole="author" affiliationRef="#af16"><personName><givenNames>David</givenNames><familyName>Nyenhuis</familyName></personName></creator><creator xml:id="au19" creatorRole="author" affiliationRef="#af17"><personName><givenNames>C. Warren</givenNames><familyName>Olanow</familyName></personName></creator><creator xml:id="au20" creatorRole="author" affiliationRef="#af18"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName></personName></creator><creator xml:id="au21" creatorRole="author" affiliationRef="#af19"><personName><givenNames>Anette</givenNames><familyName>Schrag</familyName></personName></creator><creator xml:id="au22" creatorRole="author" affiliationRef="#af20"><personName><givenNames>Jeanne A.</givenNames><familyName>Teresi</familyName></personName></creator><creator xml:id="au23" creatorRole="author" affiliationRef="#af21"><personName><givenNames>Jacobus J.</givenNames><familyName>Van Hilten</familyName></personName></creator><creator xml:id="au24" creatorRole="author" affiliationRef="#af22"><personName><givenNames>Nancy</givenNames><familyName>LaPelle</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Columbia University, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="ES" type="organization"><unparsedAffiliation>Department of Neuroepidemiology, Carlos III Institute, Madrid, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="PT" type="organization"><unparsedAffiliation>Department of Pharmacology, Faculdade de Medicina de Lisboa, Lisboa, Portugal</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="US" type="organization"><unparsedAffiliation>Biostatistics, Bioinformatics Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="DE" type="organization"><unparsedAffiliation>Department of Neurology, Friedrich‐Wilhelms University, Bonn, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="FR" type="organization"><unparsedAffiliation>Department of Neurology, Hôpital de la Salpetriere, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af10" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Rochester, Rochester, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af11" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</unparsedAffiliation></affiliation><affiliation xml:id="af12" countryCode="ES" type="organization"><unparsedAffiliation>Department of Neurology, Sant Pau Hospital, Barcelona, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af13" countryCode="CA" type="organization"><unparsedAffiliation>Division of Applied and Interventional Research, University of Toronto, Toronto, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af14" countryCode="GB" type="organization"><unparsedAffiliation>Reta Lila Weston Institute of Neurological Studies, University College, London, England</unparsedAffiliation></affiliation><affiliation xml:id="af15" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Wayne State University, Detroit, Michigan, USA</unparsedAffiliation></affiliation><affiliation xml:id="af16" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology and Rehabilitation, University of Illinois, Chicago, Illinois, USA</unparsedAffiliation></affiliation><affiliation xml:id="af17" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af18" countryCode="FR" type="organization"><unparsedAffiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse University, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af19" countryCode="GB" type="organization"><unparsedAffiliation>Department of Clinical Neurosciences, University College, London, England</unparsedAffiliation></affiliation><affiliation xml:id="af20" countryCode="US" type="organization"><unparsedAffiliation>Division of General Medicine, Columbia University, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af21" countryCode="NL" type="organization"><unparsedAffiliation>Department of Neurology, Leiden University, Leiden, The Netherlands</unparsedAffiliation></affiliation><affiliation xml:id="af22" countryCode="US" type="organization"><unparsedAffiliation>Division of Preventive and Behavioral Medicine, University of Massachusetts, Worcester, Massachusetts, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">rating scales</keyword><keyword xml:id="kwd3">Unified Parkinson's Disease Rating Scale</keyword><keyword xml:id="kwd4">clinimetrics</keyword></keywordGroup><fundingInfo><fundingAgency>Boehringer‐Ingelheim USA</fundingAgency></fundingInfo><fundingInfo><fundingAgency>GlaxoSmithKline</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Pfizer, Inc.</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)–sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS‐UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve problematic areas. An MDS‐UPDRS committee prepared the revision using the recommendations of the published critique of the scale. Subcommittees developed new material that was reviewed by the entire committee. A 1‐day face‐to‐face committee meeting was organized to resolve areas of debate and to arrive at a working draft ready for clinimetric testing. The MDS‐UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Experiences of Daily Living; III, Motor Examination; and IV, Motor Complications. All items have five response options with uniform anchors of 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Several questions in Part I and all of Part II are written as a patient/caregiver questionnaire, so that the total rater time should remain approximately 30 minutes. Detailed instructions for testing and data acquisition accompany the MDS‐UPDRS in order to increase uniform usage. Multiple language editions are planned. A three‐part clinimetric program will provide testing of reliability, validity, and responsiveness to interventions. Although the MDS‐UPDRS will not be published until it has successfully passed clinimetric testing, explanation of the process, key changes, and clinimetric programs allow clinicians and researchers to understand and participate in the revision process. © 2006 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>MDS‐UPDRS</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan</title></titleInfo><name type="personal"><namePart type="given">Christopher G.</namePart><namePart type="family">Goetz</namePart><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation><description>Correspondence: Department of Neurological Sciences, Rush University Medical Center, Suite 755, 1725 West Harrison Street, Chicago, IL 60612</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stanley</namePart><namePart type="family">Fahn</namePart><affiliation>Department of Neurology, Columbia University, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pablo</namePart><namePart type="family">Martinez‐Martin</namePart><affiliation>Department of Neuroepidemiology, Carlos III Institute, Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cristina</namePart><namePart type="family">Sampaio</namePart><affiliation>Department of Pharmacology, Faculdade de Medicina de Lisboa, Lisboa, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Glenn T.</namePart><namePart type="family">Stebbins</namePart><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Matthew B.</namePart><namePart type="family">Stern</namePart><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Barbara C.</namePart><namePart type="family">Tilley</namePart><affiliation>Biostatistics, Bioinformatics Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Richard</namePart><namePart type="family">Dodel</namePart><affiliation>Department of Neurology, Friedrich‐Wilhelms University, Bonn, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bruno</namePart><namePart type="family">Dubois</namePart><affiliation>Department of Neurology, Hôpital de la Salpetriere, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert</namePart><namePart type="family">Holloway</namePart><affiliation>Department of Neurology, University of Rochester, Rochester, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Joseph</namePart><namePart type="family">Jankovic</namePart><affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jaime</namePart><namePart type="family">Kulisevsky</namePart><affiliation>Department of Neurology, Sant Pau Hospital, Barcelona, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anthony E.</namePart><namePart type="family">Lang</namePart><affiliation>Division of Applied and Interventional Research, University of Toronto, Toronto, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andrew</namePart><namePart type="family">Lees</namePart><affiliation>Reta Lila Weston Institute of Neurological Studies, University College, London, England</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sue</namePart><namePart type="family">Leurgans</namePart><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Peter A.</namePart><namePart type="family">LeWitt</namePart><affiliation>Department of Neurology, Wayne State University, Detroit, Michigan, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David</namePart><namePart type="family">Nyenhuis</namePart><affiliation>Department of Neurology and Rehabilitation, University of Illinois, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C. Warren</namePart><namePart type="family">Olanow</namePart><affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse University, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anette</namePart><namePart type="family">Schrag</namePart><affiliation>Department of Clinical Neurosciences, University College, London, England</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jeanne A.</namePart><namePart type="family">Teresi</namePart><affiliation>Division of General Medicine, Columbia University, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jacobus J.</namePart><namePart type="family">Van Hilten</namePart><affiliation>Department of Neurology, Leiden University, Leiden, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nancy</namePart><namePart type="family">LaPelle</namePart><affiliation>Division of Preventive and Behavioral Medicine, University of Massachusetts, Worcester, Massachusetts, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-01</dateIssued><dateCaptured encoding="w3cdtf">2005-05-17</dateCaptured><dateValid encoding="w3cdtf">2006-07-14</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">1</extent><extent unit="references">6</extent><extent unit="words">5235</extent></physicalDescription><abstract lang="en">This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)–sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS‐UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve problematic areas. An MDS‐UPDRS committee prepared the revision using the recommendations of the published critique of the scale. Subcommittees developed new material that was reviewed by the entire committee. A 1‐day face‐to‐face committee meeting was organized to resolve areas of debate and to arrive at a working draft ready for clinimetric testing. The MDS‐UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Experiences of Daily Living; III, Motor Examination; and IV, Motor Complications. All items have five response options with uniform anchors of 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Several questions in Part I and all of Part II are written as a patient/caregiver questionnaire, so that the total rater time should remain approximately 30 minutes. Detailed instructions for testing and data acquisition accompany the MDS‐UPDRS in order to increase uniform usage. Multiple language editions are planned. A three‐part clinimetric program will provide testing of reliability, validity, and responsiveness to interventions. Although the MDS‐UPDRS will not be published until it has successfully passed clinimetric testing, explanation of the process, key changes, and clinimetric programs allow clinicians and researchers to understand and participate in the revision process. © 2006 Movement Disorder Society</abstract><note type="funding">Boehringer‐Ingelheim USA</note><note type="funding">GlaxoSmithKline</note><note type="funding">Pfizer, Inc.</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>rating scales</topic><topic>Unified Parkinson's Disease Rating Scale</topic><topic>clinimetrics</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>41</start><end>47</end><total>7</total></extent></part></relatedItem><identifier type="istex">F46244B722761F7710F83364D6F9965927CB98D5</identifier><identifier type="DOI">10.1002/mds.21198</identifier><identifier type="ArticleID">MDS21198</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2006 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000324 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000324 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:F46244B722761F7710F83364D6F9965927CB98D5
|texte= Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan
}}
| This area was generated with Dilib version V0.6.23. |  |